Contact Your Financial Adviser Money Making MC
17
May 2017
I had
mentioned in Tuesday’s closing report that Nifty, Sensex were trading higher.
The major indices of the Indian stock markets were range-bound on Wednesday and
closed with small gains over Tuesday’s close. The trends of the major indices
in the course of Wednesday’s trading are given in the table below: The Total Investment & Insurance
Solutions
 |
| Major Indices (The Total Investment & Insurance Solutions) |
The
key Indian equity indices touched new intra-day highs during the mid-afternoon
trade session on Wednesday, as a strong rupee and healthy buying in metal and
automobile stocks buoyed investors' sentiments. Around 2 p.m. on Wednesday, the
NSE Nifty rose by 15.40 points or 0.16% to 9,527.65 points. Investors remained
firm ahead of a crucial GST (Goods and Services Tax) panel meet in Srinagar
starting on Thursday. Both the benchmark indices touched all-time high levels.
Appreciation of the rupee against the US dollar also supported the firmness,
according to market analysts. The Total
Investment & Insurance Solutions
Bharti
Airtel on Wednesday announced new plans for its home broadband users, offering
up to 100% more high-speed data benefits within the same monthly rentals.
"Our new plans are aimed at putting India onto the digital super highway
and complement our superfast broadband offerings like ‘V-Fiber'," said
Hemanth Kumar Guruswamy, CEO - Homes, Bharti Airtel (India). In-home high speed
data consumption in India is increasing exponentially and to serve this growing
demand and enable a seamless high speed data experience in a multi-device
environment, Airtel has built a future ready network and introduced ‘V-Fiber'
that delivers consistently superfast broadband speeds of up to 100 Mbps to
homes, the company statement said. Airtel's refreshed broadband plans are
designed for ‘V-Fiber' superfast broadband. Bharti Airtel closed at Rs376.00,
up 0.35% on the BSE.
Pharma
major Dr Reddy's Laboratories Ltd has received approval from the US Food and
Drug Administration (USFDA) to launch doxorubicin hydrochloride liposome
injection, for intravenous use, in the US market. Doxorubicin hydrochloride
liposome injection is a therapeutic equivalent generic version of Doxil®
(doxorubicin hydrochloride liposome injection). The USFDA approval is an
outcome of extensive collaboration with the company's partner, Natco Pharma
Ltd. on R&D and manufacturing capabilities, the Hyderabad-based Dr Reddy's
said in a statement on Wednesday. "This approval represents the first of
its kind for Dr Reddy's in the complex depot injectables arena," explains
Alok Sonig, Executive Vice President and Head of the North America Generics
business at Dr Reddy's Laboratories. "It is a testament to our commitment
to bring affordable generic medicines to market for patients. The approval
further validates our capabilities to successfully develop and manufacture
complex liposomal formulations. We are preparing for a commercial launch
soon," he said. Dr Reddy’s Laboratories closed at Rs2,731.95, up 0.32% on
the BSE.
The
top gainers and top losers of the major indices are given in the table below:
 |
Top Gainer (The Total
Investment & Insurance Solutions)
The
closing values of the major Asian indices are given in the table below: The Total Investment & Insurance Solutions
 |
| Asian Indices (The Total Investment & Insurance Solutions) |
No comments:
Post a Comment